Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Wilmington, NC
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Columbus, OH
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Bedford, TX
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Bedford, TX
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Dallas, TX
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Draper, UT
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Draper, UT
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Charlottesville, VA
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Investigational Site Number 840025
mi
from
Burmingham, AL
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Investigational Site Number 840025
mi
from
Burmingham, AL
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
La Mesa, CA
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
La Mesa, CA
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Farmington, CT
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Farmington, CT
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Waterbury, CT
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Waterbury, CT
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
South Miami, FL
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
South Miami, FL
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Egg Harbor Township, NJ
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Egg Harbor Township, NJ
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Amherst, NY
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Amherst, NY
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Altoona, PA
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Altoona, PA
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Reading, PA
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Reading, PA
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Mt. Pleasant, SC
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Memphis, TN
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
Clinical Research Facility
mi
from
Austin, TX
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated:  8/3/2015
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
mi
from
London,
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
mi
from
London,
Click here to add this to my saved trials
Exercise Plus Activity Strategy Training for Osteoarthritis
Exercise Plus Activity Strategy Training for Older Adults With Osteoarthritis
Status: Enrolling
Updated:  8/3/2015
University of Michigan Institute of Gerontology
mi
from
Ann Arbor, MI
Exercise Plus Activity Strategy Training for Osteoarthritis
Exercise Plus Activity Strategy Training for Older Adults With Osteoarthritis
Status: Enrolling
Updated: 8/3/2015
University of Michigan Institute of Gerontology
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Patient and Provider Interventions for Managing Osteoarthritis in Primary Care
Patient and Provider Interventions for Managing Osteoarthritis in Primary Care
Status: Enrolling
Updated:  8/4/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Patient and Provider Interventions for Managing Osteoarthritis in Primary Care
Patient and Provider Interventions for Managing Osteoarthritis in Primary Care
Status: Enrolling
Updated: 8/4/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Phoenix, AZ
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Miami, FL
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Oklahoma City, OK
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Tuscon, AZ
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Tuscon, AZ
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Anahiem, CA
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Anahiem, CA
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigator Site
mi
from
Clearwater, FL
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigator Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Coral Gables, FL
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Coral Gables, FL
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Fleming Island, FL
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Fleming Island, FL
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Pinellas Park, FL
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Pinellas Park, FL
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Venice, FL
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Venice, FL
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Marietta, GA
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Marietta, GA
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
South Bend, IN
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
South Bend, IN
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Springfield, MO
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Springfield, MO
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigator Site
mi
from
Albuquerque, NM
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigator Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Statesville, NC
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Statesville, NC
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis
mi
from
San Antonio, TX
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated:  8/6/2015
Novartis Investigative Site
mi
from
Bruxelles,
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Novartis Investigative Site
mi
from
Bruxelles,
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Tucson, AZ
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
La Jolla, CA
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Victorville, CA
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Victorville, CA
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Sarasota, FL
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Rock Island, IL
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Rock Island, IL
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Springfield, IL
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Springfield, IL
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Lexington, KY
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Grand Rapids, MI
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Lansing, MI
Safety and Efficacy of AMG 827 in Subjects With RA
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials